RBC pours cold water: The likelihood of AstraZeneca (AZN.US) acquiring Bristol-Myers Squibb (BMY.US) is extremely low, with valuation differences and antitrust issues posing the biggest obstacles.

智通财经2026/08/04 01:41

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to Golden Ten Data, investment bank RBC stated that the potential acquisition of Bristol Myers Squibb (BMY.US) by AstraZeneca (AZN.US) is currently unlikely to occur.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

RBC pours cold water: The likelihood of AstraZeneca (AZN.US) acquiring Bristol-Myers Squibb (BMY.US) is extremely low, with valuation differences and antitrust issues posing the biggest obstacles.

You may also like

Crypto prices